Table 1.
Associations between RR-inducing inhibitors and anti-RR production.
| Inhibitor | Mode of action | Clinical use | Anti-RR in patients? | Major references |
|---|---|---|---|---|
| Acivicin | Glutamine analog | N/A (experimental antitumor agent) | None reported | (8) |
| Decoyinine | Nucleoside analog | N/A (experimental antitumor agent) | None reported | (11) |
| DON | Glutamine analog | N/A (experimental antitumor agent) | None reported | (8) |
| Mycophenolic acid | Inhibits IMPDH | Prevention of organ transplant rejection; lupus nephritis | None reported | (10) |
| Pemetrexed | Folate antimetabolite | Pleural mesothelioma; non-small cell lung cancer | None reported | (5) |
| Ribavirin | Inhibits IMPDH | Hepatitis C; human respiratory syncytial virus | Yes, 20–38% of HCV patientsa | (2, 3) |
DON, 6-diazo-5-oxo-l-norleucine; IMPDH, inosine monophosphate dehydrogenase;
aanti-RR observed in 20–38% of hepatitis C patients treated with pegylated interferon-α/ribavirin combination therapy.